A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

July 2, 2021 updated by: AbbVie (prior sponsor, Abbott)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Smokers

This is an efficacy study evaluating a experimental treatment for cognitive deficits in adults with schizophrenia.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Safety and Efficacy Study for Cognitive Deficits in Adult Subjects with Schizophrenia.

Study Type

Interventional

Enrollment (Actual)

157

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • Chino, California, United States, 91710
        • Site Reference ID/Investigator# 74436
      • Garden Grove, California, United States, 92845
        • Site Reference ID/Investigator# 72704
      • National City, California, United States, 91950
        • Site Reference ID/Investigator# 72699
      • Oceanside, California, United States, 92056
        • Site Reference ID/Investigator# 73983
      • Orange, California, United States, 92868
        • Site Reference ID/Investigator# 73236
      • San Diego, California, United States, 92102
        • Site Reference ID/Investigator# 86974
      • Torrance, California, United States, 90502
        • Site Reference ID/Investigator# 72701
    • Florida
      • Bradenton, Florida, United States, 34201
        • Site Reference ID/Investigator# 75314
      • Maitland, Florida, United States, 32751
        • Site Reference ID/Investigator# 75146
    • Georgia
      • Atlanta, Georgia, United States, 30308
        • Site Reference ID/Investigator# 75654
    • Illinois
      • Chicago, Illinois, United States, 60640
        • Site Reference ID/Investigator# 72703
      • Hoffman Estates, Illinois, United States, 60169
        • Site Reference ID/Investigator# 76534
    • Louisiana
      • Lake Charles, Louisiana, United States, 70629
        • Site Reference ID/Investigator# 73984
    • Missouri
      • Saint Louis, Missouri, United States, 63109
        • Site Reference ID/Investigator# 73981
    • New Jersey
      • Marlton, New Jersey, United States, 08053
        • Site Reference ID/Investigator# 89553
    • New York
      • Cedarhurst, New York, United States, 11516
        • Site Reference ID/Investigator# 72700
      • New York, New York, United States, 10065
        • Site Reference ID/Investigator# 73982
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73116
        • Site Reference ID/Investigator# 113035
    • Texas
      • DeSoto, Texas, United States, 75115
        • Site Reference ID/Investigator# 72702
      • Houston, Texas, United States, 77008
        • Site Reference ID/Investigator# 75147

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 55 years (ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Has a current Diagnostic and Statistical Manual of Mental Disorders-, 4th Edition, Text Revision (DSM-IV-TR) diagnosis of schizophrenia confirmed by the Mini-International Neuropsychiatric Interview (M.I.N.I.).
  • Is clinically stable while receiving a regimen of one or two allowable antipsychotic medications; lack of hospitalizations in 4 months prior to initial screening visit; taking the same antipsychotic medication(s) for at least 8 weeks prior to baseline visit; core positive symptoms of Positive and Negative Syndrome Scale (PANSS) no worse than moderate in severity throughout screening period of at least 4 weeks.
  • Has been diagnosed with or treated for schizophrenia for at least 2 years prior to initial screening visit.
  • Has had continuity in psychiatric care (e.g., mental health system, clinic or physician) for at least 6 months prior to initial screening visit.
  • Has an identified contact person (e.g., family member, social worker, case worker, or nurse) that can provide support to the subject to ensure compliance with protocol requirements.

Exclusion Criteria:

  • In the Investigator's judgment, has a current or past diagnosis of schizoaffective disorder, bipolar disorder, manic episode, dementia, post traumatic stress disorder, or obsessive-compulsive disorder, or the subject has a current major depressive episode.
  • Has a positive urine drug screen for cocaine, phencyclidine (PCP), opiates (unless duly prescribed), benzodiazepines (unless duly prescribed), marijuana, or amphetamines during the Screening Period.
  • Has a current or past history of seizures, with the exception of a single febrile seizure occurring prior to 6 years of age.
  • Has a clinically significant abnormal electrocardiogram (ECG) at Screening Visit 1 as determined by the Investigator.
  • Has any risk factors for Torsades de Pointes (TdP)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: TRIPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
PLACEBO_COMPARATOR: Placebo
Drug: Placebo
Placebo
EXPERIMENTAL: ABT-126 Low Dose
Drug: ABT-126
ABT-126 Low Dose
Drug: ABT-126
ABT-126 High Dose
EXPERIMENTAL: ABT-126 High Dose
Drug: ABT-126
ABT-126 Low Dose
Drug: ABT-126
ABT-126 High Dose

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cognition: MCCB (MATRICS Consensus Cognitive Battery) change from baseline to week 12
Time Frame: Change from baseline to week 12
Rater based interview
Change from baseline to week 12

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Functioning: UPSA-2 (University of California San Diego Performance-based Skills Assessment-2)
Time Frame: Measurements from screening period up through week 12
Rater based interview
Measurements from screening period up through week 12
Symptom Severity: PANSS (Positive and Negative Syndrome Scale)
Time Frame: Measurements from screening period up through week 12
Rater based interview
Measurements from screening period up through week 12
Symptom Severity: NSA-16 (16-item version of the Negative Symptom Assessment Scale)
Time Frame: Measurements from screening period up through week 12
Rater based interview
Measurements from screening period up through week 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AbbVie (prior sponsor, Abbott)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2012

Primary Completion (ACTUAL)

March 1, 2014

Study Completion (ACTUAL)

March 1, 2014

Study Registration Dates

First Submitted

August 31, 2012

First Submitted That Met QC Criteria

September 4, 2012

First Posted (ESTIMATE)

September 5, 2012

Study Record Updates

Last Update Posted (ACTUAL)

July 7, 2021

Last Update Submitted That Met QC Criteria

July 2, 2021

Last Verified

July 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • M13-608

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Schizophrenia

Clinical Trials on Placebo

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe